ProShare Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

ProShare Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-9,009	Closed	-$677K	–	1829
2022 Q2	$677K	Sell	9,009 -4,751	-35%	-$211K	﹤0.01%	847
2022 Q1	$370K	Sell	13,760 -3,250	-19%	-$109K	﹤0.01%	1492
2021 Q4	$810K	Buy	17,010 +560	+3%	+$25K	﹤0.01%	1157
2021 Q3	$1.09M	Sell	16,450 -4,311	-21%	-$307K	﹤0.01%	879
2021 Q2	$1.62M	Buy	20,761 +4,117	+25%	+$304K	﹤0.01%	796
2021 Q1	$1.57M	Buy	16,644 +939	+6%	+$112K	﹤0.01%	776
2020 Q4	$1.91M	Buy	15,705 +4,721	+43%	+$517K	0.01%	648
2020 Q3	$960K	Buy	10,984 +592	+6%	+$41.2K	﹤0.01%	730
2020 Q2	$671K	Buy	10,392 +3,835	+58%	+$221K	﹤0.01%	827
2020 Q1	$293K	Sell	6,557 -4,948	-43%	-$263K	﹤0.01%	883
2019 Q4	$717K	Buy	+11,505	New	+$547K	﹤0.01%	924

ProShare Advisors's TPTX Position: Q3 2022 in Review

ProShare Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 9,009 shares — an estimated $677K sold.

ProShare Advisors first reported a position in TPTX in Q4 2019 and held it in 11 quarters. The position peaked at $1.91M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

ProShare Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
ProShare Advisors sold 9,009 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $677K.
ProShare Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
ProShare Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.91M in Q4 2020.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on ProShare Advisors's 13F filing for Q3 2022, filed 7 Nov 2022.